A Phase 3 interventional study of eptacog alfa (activated) and placebo in Acquired Bleeding Disorder and Trauma, sponsored by Novo Nordisk A/S. Terminated at 14 sites in 14 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-06-25.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial is conducted globally. The purpose of the trial is to evaluate that activated recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely injured trauma patients by assessing mortality and morbidity.
Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been merged.
The decision to discontinue the F7TRAUMA-1711 trial is not due to any safety concerns. The result of the pre-planned futility analysis performed in June 2008 predicted a very low likelihood of reaching a successful outcome on the primary efficacy endpoint at the end of the trial and as a consequence, the company has decided to close the trial as this juncture.
2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.
This study's enrollment of 554 is above the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: eptacog alfa (activated)
Drug: placebo
Drug: eptacog alfa (activated)
Drug: placebo
Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection. Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours.
placebo
Mortality
Number of participants to die from day 0 to day 30 from all causes.
Time frame: from day 0 to 30
Morbidity
Morbidity reflects the number of patients who had pulmonary and/or renal dysfunction requiring ongoing medical intervention on day 30.
Time frame: from day 0 to day 30
Number of Days Alive and Free of Pulmonary and/or Renal Dysfunction Requiring Medical Intervention
The number of days alive and free of pulmonary and/or renal dysfunction requiring medical intervention from day 0 to day 30.
Time frame: from day 0 to day 30
Time to Death From Time of First Dose
The time of first dose refers to the time of the first dose of rFVIIa or placebo.
Time frame: from day 0 to day 30
Number of Units of Transfused Red Blood Cells From Time of First Dose
The number of units of transfused red blood cells in the first 24 hours from the time of the first dose of rFVIIa or placebo.
Time frame: from hour 0 to 24
Number of Patients Receiving 10 Units or More (Massive Transfusion) of Red Blood Cells From Time of Injury
The number of patients receiving 10 units or more of red blood cells in the first 24 hours from the time of injury.
Time frame: from hour 0 to 24
Number of Units of All Allogeneic Transfusions From Time of First Dose
The number of units of all allogeneic transfusions in the first 24 hours from the time of the first dose of rFVIIa or placebo.
Time frame: from hour 0 to 24
150 trial sites globally.
| Milestone | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| Started | 226 | 255 | 47 | 45 |
| Exposed | 224 | 250 | 46 | 40 |
| Completed | 218 | 242 | 44 | 38 |
| Not completed | 8 | 13 | 3 | 7 |
Number of participants to die from day 0 to day 30 from all causes.
| Participants | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| Mortality | 24 | 26 | — | — |
Morbidity reflects the number of patients who had pulmonary and/or renal dysfunction requiring ongoing medical intervention on day 30.
No measurements were reported for this outcome.
The number of days alive and free of pulmonary and/or renal dysfunction requiring medical intervention from day 0 to day 30.
| Days | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| Number of Days Alive and Free of Pulmonary and/or Renal Dysfunction Requiring Medical Intervention | 17.2 ± 10.3 | 16.4 ± 10.3 | — | — |
The time of first dose refers to the time of the first dose of rFVIIa or placebo.
No measurements were reported for this outcome.
The number of units of transfused red blood cells in the first 24 hours from the time of the first dose of rFVIIa or placebo.
| Units of transfused red blood cells | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| Number of Units of Transfused Red Blood Cells From Time of First Dose | 6.9 ± 10.4 | 8.1 ± 10.9 | — | — |
The number of patients receiving 10 units or more of red blood cells in the first 24 hours from the time of injury.
| Participants | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| Number of Patients Receiving 10 Units or More (Massive Transfusion) of Red Blood Cells From Time of Injury | 111 | 134 | — | — |
The number of units of all allogeneic transfusions in the first 24 hours from the time of the first dose of rFVIIa or placebo.
| Units of allogeneic transfusions | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| Number of Units of All Allogeneic Transfusions From Time of First Dose | 17.1 ± 26.8 | 20.7 ± 25.7 | — | — |
Collected over Adverse events were collected in a timespan of 90 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rFVIIa, Blunt Trauma | — | 147/224 (65.6%) | 108/224 (48.2%) |
| Placebo, Blunt Trauma | — | 177/250 (70.8%) | 125/250 (50%) |
| rVIIa, Penetrating Trauma | — | 18/46 (39.1%) | 26/46 (56.5%) |
| Placebo, Penetrating Trauma | — | 20/40 (50%) | 24/40 (60%) |
| Event | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| SepsisInfections and infestations | 24/224 | 30/250 | 3/46 | 2/40 |
| PneumoniaInfections and infestations | 11/224 | 26/250 | 3/46 | 2/40 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 8/224 | 18/250 | 0/46 | 3/40 |
| Multi-organ failureGeneral disorders | 10/224 | 17/250 | 1/46 | 1/40 |
| Deep vein thrombosisVascular disorders | 14/224 | 14/250 | 0/46 | 2/40 |
| Small intestinal obstructionGastrointestinal disorders | 0/224 | 0/250 | 0/46 | 2/40 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 6/224 | 1/250 | 2/46 | 2/40 |
| Septic shockInfections and infestations | 5/224 | 12/250 | 0/46 | 0/40 |
| Cardiac arrestCardiac disorders | 7/224 | 8/250 | 2/46 | 1/40 |
| Renal failureRenal and urinary disorders | 3/224 | 3/250 | 2/46 | 0/40 |
| Event | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rVIIa, Penetrating Trauma | Placebo, Penetrating Trauma |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 27/224 | 27/250 | 11/46 | 14/40 |
| TachycardiaCardiac disorders | 12/224 | 13/250 | 6/46 | 2/40 |
| HypokalaemiaMetabolism and nutrition disorders | 28/224 | 32/250 | 5/46 | 3/40 |
| HypomagnesaemiaMetabolism and nutrition disorders | 21/224 | 28/250 | 5/46 | 5/40 |
| HypocalcaemiaMetabolism and nutrition disorders | 25/224 | 30/250 | 4/46 | 3/40 |
| HypertensionVascular disorders | 0/224 | 0/250 | 5/46 | 3/40 |
| HypotensionVascular disorders | 24/224 | 25/250 | 4/46 | 4/40 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/224 | 0/250 | 1/46 | 4/40 |
| HypophosphataemiaMetabolism and nutrition disorders | 6/224 | 14/250 | 4/46 | 2/40 |
| HypothermiaGeneral disorders | 15/224 | 21/250 | 0/46 | 0/40 |
| Age, Continuous(years) | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma | Total |
|---|---|---|---|---|---|
| Mean | 39.2 ± 14.4 | 39.9 ± 14.2 | 33.8 ± 11.9 | 29.4 ± 10.3 | 38.4 ± 14.1 |
| Sex: Female, Male(Participants) | rFVIIa, Blunt Trauma | Placebo, Blunt Trauma | rFVIIa, Penetrating Trauma | Placebo, Penetrating Trauma | Total |
|---|---|---|---|---|---|
| Female | 59 | 65 | 3 | 3 | 130 |
| Male | 162 | 182 | 43 | 37 | 424 |
The record gives a start of Oct 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recombinant FVIIa